Latest Breaking News On - Deciphera pharmaceuticals stock - Page 1 : vimarsana.com

Zacks Research Weighs in on Deciphera Pharmaceuticals, Inc s Q1 2025 Earnings (NASDAQ:DCPH)

Zacks Research Weighs in on Deciphera Pharmaceuticals, Inc s Q1 2025 Earnings (NASDAQ:DCPH)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesZacks researchHedge funds weigh in on deciphera pharmaceuticalsNews ratings for deciphera pharmaceuticals dailyPrincipal financial group incJpmorgan chase coDeciphera pharmaceuticals incChina universal asset management coJefferies financial groupPanagora asset management incDeciphera pharmaceuticalsDeciphera pharmaceuticals stockFree reportDeciphera pharmaceuticalFinancial groupGet free report

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc - DCPH

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc - DCPH
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesLewiss kahnCharlesc foti jrDeciphera pharmaceuticals incCo ltdDeciphera pharmaceuticals stockKahn swick fotiFormer attorney generalLouisiana charlesKahn swickDeciphera pharmaceuticalsPartner lewisFormer louisiana attorney general

Analysts Issue Forecasts for Deciphera Pharmaceuticals, Inc s FY2026 Earnings (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Equities researchers at Zacks Research issued their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a research report issued on Tuesday, February 27th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings of ($1.25) per share for the year. The consensus estimate for […]

United statesMatthewl shermanStifel nicolausChina universal asset management coPrincipal financial group incGroup plcDeciphera pharmaceuticals incDeciphera pharmaceuticals stockNews ratings for deciphera pharmaceuticals dailyDeciphera pharmaceuticalsZacks researchJpmorgan chase coSecurities exchange commissionDana investment advisors incFree reportDeciphera pharmaceutical

Q1 2024 EPS Estimates for Deciphera Pharmaceuticals, Inc (NASDAQ:DCPH) Boosted by HC Wainwright

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Research analysts at HC Wainwright raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a report issued on Wednesday, February 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.63) per share for the quarter, up from their previous estimate […]

United statesMatthewl shermanPiper sandlerStifel nicolausDeciphera pharmaceuticalsDeciphera pharmaceuticals stockHedge funds weigh in on deciphera pharmaceuticalsChina universal asset management coDeciphera pharmaceuticals company profileJpmorgan chase coCompass wealth managementDeciphera pharmaceuticals incQuest partnersNews ratings for deciphera pharmaceuticals dailyAdvisor group holdings incFree report

Deciphera Pharmaceuticals, Inc (NASDAQ:DCPH) Receives $22 56 Consensus Price Target from Analysts

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the […]

United statesStifel nicolausPiper sandlerMatthewl shermanLazard asset managementJpmorgan chase coAdvisor group holdings incDeciphera pharmaceuticals incCompass wealth managementDeciphera pharmaceuticals company profileDeciphera pharmaceuticals stockDeciphera pharmaceuticalsSecurities exchange commissionAnalyst recommendations for deciphera pharmaceuticalsNews ratings for deciphera pharmaceuticals dailyChina universal asset management co